AureoGen Biosciencesâ primary focus is the development of novel, genetic engineering technologies for the discovery and production of cyclic peptide-based drugs. Until recently, any structural modifications required for conversion of a native cyclic peptide molecule into a functional drug had to be introduced by complicated and expensive synthetic chemistry. This hampered the development of promising drug candidates, as well as prevented optimization (such as reduction of side effects) of many existing drugs. The company focuses on naturally produced drugs isolated from microorganisms, such as bacteria and fungi
